Message from the Senior Vice President for Health Sciences
Michael D. Dake, MD
Reflecting on a Remarkable Year
As we approach the end of the fall semester and look ahead to the holiday season, I want to recognize our faculty, staff and students who have come together this year like never before, and who have worked relentlessly to continue fulfilling our mission of improving human health and potential through education, research and outreach, even in the midst of a worldwide crisis.
Dual Inhibitor Strategy May Be Key to Sustainable COVID-19 Treatment
Researchers in the College of Pharmacy say compounds targeting proteins involved in viral replication may further drug development for treating COVID-19.
Pharma Company Licenses UArizona Method for Treating Parkinson's Disease with Ketamine
In pre-clinical studies, researchers found that low-dose ketamine infusions can improve pain, depression and levodopa-induced dyskinesia in Parkinson's patients.
Pharma Company Licenses UArizona Method for Treating Parkinson's Disease with Ketamine
In pre-clinical studies, researchers found that low-dose ketamine infusions can improve pain, depression and levodopa-induced dyskinesia in Parkinson's patients.
Dual Inhibitor Strategy May Be Key to Sustainable COVID-19 Treatment
Researchers in the College of Pharmacy say compounds targeting proteins involved in viral replication may further drug development for treating COVID-19.
Pharma Company Licenses UArizona Method for Treating Parkinson's Disease with Ketamine
In pre-clinical studies, researchers found that low-dose ketamine infusions can improve pain, depression and levodopa-induced dyskinesia in Parkinson's patients.
Dual Inhibitor Strategy May Be Key to Sustainable COVID-19 Treatment
Researchers in the College of Pharmacy say compounds targeting proteins involved in viral replication may further drug development for treating COVID-19.
